Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobicistat/darunavir - Janssen R&D Ireland

Next Previous
Drug Profile

Cobicistat/darunavir - Janssen R&D Ireland

Alternative Names: Darunavir/cobicistat; DRV/COBI; G 006; JNJ-48763364/TMC114; Prezcobix; Rezolsta; TMC114/ JNJ-48763364

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland; Janssen Research & Development
  • Class Antiretrovirals; Carbamates; Deoxyribonucleosides; Morpholines; Purines; Pyrimidine nucleosides; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Cytochrome P-450 enzyme system inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for phase-I development in HIV-1-infections(In adolescents, In children, In the elderly, In adults) in South Africa (PO, Tablet)
  • 28 Oct 2025 No recent reports of development identified for phase-I development in HIV-1-infections(In adolescents, In children, In the elderly, In adults) in USA (PO, Tablet)
  • 28 Sep 2025 No recent reports of development identified for phase-I development in HIV-1-infections(In adolescents, In children, In the elderly, In adults) in Spain (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top